137 related articles for article (PubMed ID: 11426837)
1. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
Acquas E; Pisanu A; Marrocu P; Goldberg SR; Di Chiara G
Eur J Pharmacol; 2001 May; 419(2-3):155-61. PubMed ID: 11426837
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
Acquas E; Pisanu A; Marrocu P; Di Chiara G
Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
5. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
Gessa GL; Mascia MS; Casu MA; Carta G
Eur J Pharmacol; 1997 May; 327(1):R1-2. PubMed ID: 9185841
[TBL] [Abstract][Full Text] [Related]
7. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
8. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
9. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
10. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
Gifford AN; Samiian L; Gatley SJ; Ashby CR
Eur J Pharmacol; 1997 Apr; 324(2-3):187-92. PubMed ID: 9145770
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
12. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
Ko MC; Woods JH
Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
[TBL] [Abstract][Full Text] [Related]
13. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
14. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.
Petitet F; Jeantaud B; Reibaud M; Imperato A; Dubroeucq MC
Life Sci; 1998; 63(1):PL1-6. PubMed ID: 9667767
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats.
da Silva GE; Fernandes MS; Takahashi RN
Neurosci Lett; 2003 Sep; 349(1):49-52. PubMed ID: 12946584
[TBL] [Abstract][Full Text] [Related]
16. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration.
Nava F; Carta G; Battasi AM; Gessa GL
Br J Pharmacol; 2000 Jul; 130(6):1201-10. PubMed ID: 10903956
[TBL] [Abstract][Full Text] [Related]
17. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination.
Wiley JL; Martin BR
Pharmacol Biochem Behav; 1999 Nov; 64(3):519-22. PubMed ID: 10548265
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
20. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
Maneuf YP; Nash JE; Crossman AR; Brotchie JM
Eur J Pharmacol; 1996 Jul; 308(2):161-4. PubMed ID: 8840127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]